Autres langues Modalis Therapeutics Corporation

Actions

4883

JP3922600006

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
31,00 ^JPY	0,00%		0,00%	-44,64%

11/09	Exegenesis Bio et Modalis Therapeutics Corporation collaborent pour faire progresser le MDL-201 contre la dystrophie musculaire de Duchenne	CI
10/08	Modalis Therapeutics Corporation publie ses résultats pour le semestre clos le 30 juin 2026	CI

Autres langues

11/09	Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy
11/09	Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
10/08	Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026
12/06	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC
27/05	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC
13/05	Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
12/02	Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025
25/12	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
25/08/25	Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC
07/08/25	Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC
07/07/25	Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment
16/06/25	Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan
09/06/25	SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
13/05/25	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
01/05/25	Modalis Issues 21,900 Shares for Restricted Stock Remuneration
27/01/25	Modalis Therapeutics Secures Japanese Patent for Gene Therapy
06/01/25	JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease
06/01/25	Jcr Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation Announces Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
06/01/25	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
28/10/24	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration
25/10/24	Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
30/09/24	Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
30/09/24	Modalis Therapeutics Corporation Receives FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
24/09/24	Modalis to Present Epigenome Editing Data at Genome Editing Summit
18/09/24	Japanese Shares Climb As Yen Strengthens Ahead of Fed Rate Decision